文献速递神经肿瘤

基于T细胞的疗法克服胶质瘤微环境中的神经解剖与免疫抑制挑战

T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
PubMed 文献 · J Neurooncol · 2020-03-17

本文综述胶质母细胞瘤微环境的神经解剖与免疫抑制特征,以及T细胞疗法(包括个性化疫苗和嵌合抗原受体T细胞疗法)为克服这些挑战所做的创新。血脑屏障限制免疫进入肿瘤微环境,恶性胶质瘤可激活适应性反应颠覆抗癌免疫并重建免疫抑制环境。

要点

  • 胶质母细胞瘤是最常见且最具侵袭性的成人原发性脑肿瘤。
  • 血脑屏障限制免疫细胞进入肿瘤微环境。
  • 恶性胶质瘤可激活适应性反应颠覆抗癌免疫并重建免疫抑制环境。

核心结论

  • 淋巴细胞脑内浸润的证据及细胞工程技术的进展提示神经肿瘤免疫治疗具有广阔前景。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 血脑屏障的复杂结构限制免疫进入肿瘤微环境。
  • 恶性胶质瘤可激活多种适应性反应以颠覆抗癌免疫反应并重建免疫抑制环境。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma remains as the most common and aggressive primary adult brain tumor to date. Within the last decade, cancer immunotherapy surfaced as a broadly successful therapeutic approach for a variety of cancers. However, due to the neuroanatomical and immunosuppressive nature of malignant gliomas, conventional chemotherapy and radiotherapy treatments garner limited efficacy in patients with these tumors. The intricate structure of the blood brain barrier restricts immune accessibility into the tumor microenvironment, and malignant gliomas can activate various adaptive responses to subvert anticancer immune responses and reinstate an immunosuppressive milieu. Yet, evidence of lymphocyte infiltration within the brain and recent advancements made in cell engineering technologies implicate the vast potential in the future of neuro-oncological immunotherapy. Previous immunotherapy platforms have paved way to improved modalities, which includes but is not limited to personalized vaccines and chimeric antigen receptor T-cell therapy. This review will cover the various neuroanatomical and immunosuppressive features of central nervous system tumors and highlight the innovations made in T-cell based therapies to overcome the challenges presented by the glioblastoma microenvironment.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Kwok D, Okada H. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. J Neurooncol. 2020. PMID: 32185647. doi:10.1007/s11060-020-03450-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。